Cover Image

Evaluating the Safety and Efficacy of a Highly Viscous 33-mg/mL Hyaluronic Acid Volumizing Filler in the Treatment of Facial Wrinkles: An Open-Labeled, Clinical Trials

Elnaz Razavian, Setareh Tehrani
Background: The 33-mg/mL hyaluronic acid (HA) formulation is a highly concentrated, cross-linked, cohesive, smooth, and completely reversible volumizing filler approved by Conformité Européene. For the first time, we aimed to evaluate the long-term efficacy and safety of the 33-mg/mL HA filler for soft tissue augmentation in the treatment of facial wrinkles. Materials and Methods: After optimal wrinkle correction was achieved in the patients undergoing treatment by injecting the 33-mg/mL HA filler at the injection site plus one touch-up at a 2-week interval, the safety and efficacy of the filler were assessed on the 5-point Facial Volume Loss Scale through the 1-year study period. Patients were evaluated daily for 14 days and after 6 and 12 months post-treatment. Results: A total of 86 subjects were treated. The mean wrinkle scores of the patients were 3.95+0.79 (range of 3-5) before treatment, 2.3+0.94 (range 1-5) six months after treatment, and 2.93+1.29 (range of 1-5) one year after treatment. Clinically significant mean wrinkle correction (P=0.001) was still evident at>12 months of treatment through 33-mg/mL HA formulation. A clinically significant correction at>12 months after treatment was maintained by 79% of patients. Nodule formation and swelling were more frequent when the 33-mg/mL HA filler was used compared with the use of less concentrated HA fillers. One patient developed angioedema-like swelling and induration last few months. Conclusion: The 33-mg/mL HA filler can provide long-term correction lasting for one year or more. Adverse effects, especially swelling and nodule formation were more common in this filler compared with less concentrated HA fillers. The side effects were correlated with the volume of the injected filler. We recommend using this concentration with low volume or combining high volume with lower concentration. [GMJ.2019;8:e1148]
Hyaluronic Acid; Wrinkles; Aging Face; Dermal Filler

Smith L, Cockerham K. Hyaluronic acid dermal fillers: can adjunctive lidocaine improve patient satisfaction without decreasing efficacy or duration?. Patient Prefer Adherence. 2011;5:133-9

PMid:21448297 PMCid:PMC3063660

Levy PM, Boulle KD, Raspaldo H. A split-face comparison of a new hyaluronic acid facial filler containing pre-incorporated lidocaine versus a standard hyaluronic acid facial filler in the treatment of nasolabial folds. J Cosmet Laser Ther. 2009;11(3):169-73.


Puizina-Ivic' N . Skin aging. Acta Dermatovenerol Alp Pannonica Adriat .2008;17(2):47-54.

Choi WJ, Han SW, Kim JE, Kim HW, Kim MB, Kang H. The efficacy and safety of lidocaine-containing hyaluronic acid dermal filler for treatment of nasolabial folds: a multicenter, randomized clinical study. Aesthetic Plast Surg. 2015;39(6):953-62.


Flament F, Bazin R, Laquieze S, Rubert V, Simonpietri E, Piot B. Effect of the sun on visible clinical signs of aging in Caucasian skin. Clin Cosmet Investig Dermatol. 2013;6:221-32.

PMid:24101874 PMCid:PMC3790843

Ho D, Jagdeo J. Biological properties of a new volumizing hyaluronic acid filler: a systematic review. J Drugs Dermatol. 2015;14(1):50-4.

Edwards PC, Fantasia JE. Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers. Clin Interv Aging. 2007;2(4):509-19.

Requena L, Requena C, Christensen L, Zimmermann US, Kutzner H, Cerroni L. Adverse reactions to injectable soft tissue fillers. J Am Acad Dermatol. 2011;64(1):1-34.


Matarasso SL, Herwick R. Hypersensitivity reaction to nonanimal stabilized hyaluronic acid. J Am Acad Dermatol. 2006;55(1):128-31.


Tezel A, Fredrickson GH. The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther. 2008;10(1):35-42.


Micheels P. Human Anti-Hyaluronic Acid Antibodies: Is it Possible?. Dermatol Surg. 2001;27(2):185-91.


Lamperle G, Holmes RE, Cohen SR, Lamperle SM. A classification of facial wrinkles. Plast Reconstr Surg. 2001;108(6):1735-50.

Pinsky MA, Thomas JA, Murphy DK, Walker PS, Group JvZNFS. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J. 2008;28(1):17-23.


Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am. 2007;15(1):63-76.


Arsiwala SZ. Safety and persistence of non-animal stabilized hyaluronic acid fillers for nasolabial folds correction in 30 Indian patients. J Cutan Aesthet Surg. 2010;3(3):156-61.

PMid:21430828 PMCid:PMC3047733

Elevess [package insert] Woburn MA: Anika Therapeutics Inc, 2007.

Baumann LS, Shamban AT, Lupo MP, Monheit GD, Thomas JA, Murphy DK et al. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: A multicenter, double-masked, randomized, within-subject study. Dermatol Surg. 2007;33(s2):128-35.


Brandt FS, Cazzaniga A. Hyaluronic acid gel fillers in the management of facial aging. Clin Interv Aging. 2008;3(1):153-9.

PMid:18488885 PMCid:PMC2544360

Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. J Eur Acad Dermatol Venereol. 2008;22(2):150-61.


Hanke CW. Evolution of filler materials in dermatology. J Am Acad Dermatol. 2013;68(5):858-9.


Luebberding S, Alexiades-Armenakas M. Safety of dermal fillers. J Drugs Dermatol. 2012;11(9):1053-8.

Gilbert E, Hui A, Waldorf H. The basic science of dermal fillers: past and present Part I: background and mechanisms of action. J Drugs dermatol. 2012;11(9):1059-68.

Piacquadio D, Jarcho M, Goltz R. Evaluation of hylan b gel as a soft-tissue augmentation implant material. J Am Acad Dermatol. 1997;36(4):544-9.

Prigent-Combaret C, Vidal O, Dorel C, Lejeune P. Abiotic surface sensing and biofilm-dependent regulation of gene expression in Escherichia coli. J Bacteriol. 1999;181(19):5993-6002.

Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg. 2009;35(s2):1672-80.


Hoffmann K. Volumizing effects of a smooth, highly cohesive, viscous 20-mg/mL hyaluronic acid volumizing filler: prospective European study. BMC Dermatol. 2009;9(1):9.

PMid:19712480 PMCid:PMC2749012

Lowe NJ, Maxwell CA, Lowe P, Duickb MG, Shah K. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol. 2001;45(6):930-3.


Andre P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA-Q-Medical, Sweden) in European countries: a retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol. 2004;18(4):422-5.


Leonhardt JM, Lawrence N, Narins RS. Angioedema acute hypersensitivity reaction to injectable hyaluronic acid. Dermatol Surg. 2005;31(5):577-9.


Klein AW. Letter to the editor: re: hypersensitivity reactions to injectable hyaluronic acid: reality or fantasy?. Dermatol Surg. 2005;31(12):1745.


Park T-H, Seo S-W, Kim J-K, Chang C-H. Clinical experience with hyaluronic acid-filler complications. J Plast Reconstr Aesthet Surg. 2011;64(7):892-6.



  • There are currently no refbacks.